Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Dengler

Showing results (241-250 of 246) with videos related to

Pageof 25
Sort By:
You have reached the last page of results.This site can display upto 246 results.
Leukemia|February 14, 2015
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IVL Kalmanti, S Saussele, M Lauseker, et al.
Leukemia|May 7, 2014
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinibB Hanfstein, V Shlyakhto, M Lauseker, et al.
Leukemia|January 12, 2017
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CMLC Schütz, S Inselmann, S Saussele, et al.
Leukemia|January 31, 2018
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CMLC Schütz, S Inselmann, S Saussele, et al.
Leukemia|March 27, 2012
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)B Hanfstein, M C Müller, R Hehlmann, et al.
Leukemia|August 15, 2017
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsR Hehlmann, M Lauseker, S Saußele, et al.
Pageof 25

Showing results (241-250 of 246) with videos related to

Sort By:
Pageof 25
You have reached the last page of results.This site can display upto 246 results.
Leukemia|February 14, 2015
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IVL Kalmanti, S Saussele, M Lauseker, et al.
Leukemia|May 7, 2014
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinibB Hanfstein, V Shlyakhto, M Lauseker, et al.
Leukemia|January 12, 2017
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CMLC Schütz, S Inselmann, S Saussele, et al.
Leukemia|January 31, 2018
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CMLC Schütz, S Inselmann, S Saussele, et al.
Leukemia|March 27, 2012
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)B Hanfstein, M C Müller, R Hehlmann, et al.
Leukemia|August 15, 2017
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsR Hehlmann, M Lauseker, S Saußele, et al.
Pageof 25